MedTrace Logo

The Role of the Kidneys and Liver in the Elimination of Glucagon

NCT05056584 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-05-12

No results posted yet for this study

Summary

The study aims to evaluate the kinetics and effect of glucagon in patients with chronic kidney disease and liver cirrhosis and matched healthy subjects, respectively.

Conditions

Interventions

BIOLOGICAL

Glucagon infusion

One hour glucagon-clamp followed by one hour of blood sampling

BIOLOGICAL

Primed tracer infusion

Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,

Sponsors & Collaborators

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · Center for Metabolic Research, Gentofte Hospital

  • Magnus FG Grøndahl, MD · Center for Metabolic Research, Gentofte Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2023-03-28
Completion
2023-03-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056584 on ClinicalTrials.gov